Literature DB >> 16308252

Auditory pathway in rheumatoid arthritis. A comparative study and surgical perspectives.

Fabrizio Salvinelli1, Luca D'Ascanio, Manuele Casale, Marta Vadacca, Amelia Rigon, Antonella Afeltra.   

Abstract

CONCLUSION: Rheumatoid arthritis (RA) patients present with both conductive and sensorineural deafness.
OBJECTIVE: To evaluate the prevalence and features of hearing impairment in patients with RA.
MATERIAL AND METHODS: A total of 28 RA patients underwent a rheumatological evaluation, including determination of rheumatoid factor, protein 2-glycoprotein I level and the Lee index. An audiological assessment consisting of pure-tone audiometry (PTA) and determination of auditory brainstem responses (ABRs) and transient evoked otoacoustic emissions (TEOAEs) was performed. The results were compared with those of 28 age- and sex-matched healthy subjects. Four selected RA patients underwent stapedectomy; PTA and TEOAEs were evaluated 6 months postoperatively.
RESULTS: Increased air conduction thresholds at 250, 500 and 1000 Hz were found in RA subjects in comparison to controls (p<0.001). RA patients showed higher air-bone gaps in PTA (p<0.05) and an increased Wave I latency in ABRs (p=0.03). Decreased reproducibility (p<0.001) and amplitude (p<0.001) of TEOAEs were found in RA subjects in comparison to controls. A significant correlation between disease duration and echo amplitude was noticed (r=0.389). After stapedectomy, a reduction in the air-bone conduction gap (11 vs 2 dB HL) was noticed; no significant difference in TEOAEs was found.

Entities:  

Mesh:

Year:  2006        PMID: 16308252     DOI: 10.1080/00016480510012264

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  1 in total

1.  Hearing impairment in patients with rheumatoid arthritis: association with anti-citrullinated protein antibodies.

Authors:  Fabrício Silva Lobo; Mario Orlando Dossi; Lígia Batista; Márcia Midori Shinzato
Journal:  Clin Rheumatol       Date:  2016-04-26       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.